Document Classification

Section Type: RESULTS

Text: Patients receiving continuous fingolimod showed persistent benefits in ARR (0. 5 mg fingolimod [n = 356], 0. 12 [95 % CI 0. 08-0. 17] in months 0-12 vs 0. 11 [0. 08-0. 16] in months 13-24 ; 1. 25 mg fingolimod [n = 330], 0. 15 [0. 10-0. 21] vs 0. 11 [0. 08-0. 16] ; however, in patients who initially received interferon beta-1a, ARR was lower after switching to fingolimod compared with the previous 12 months (interferon beta-1a to 0. 5 mg fingolimod [n = 167], 0. 31 [95 % CI 0. 22-0. 43] in months 0-12 vs 0. 22 [0. 15-0. 31], in months 13-24 p = 0. 049 ; interferon beta-1a to 1. 25 mg fingolimod [n = 174], 0. 29 [0. 20-0. 40] vs 0. 18 [0. 12-0. 27], p = 0. 024).